Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.

Serum samples from 82 patients with epithelial ovarian cancer, previously assayed for CA125, were assayed for circulating colony-stimulating factor 1 (CSF-1). An elevated CSF-1 concentration (> 450 U ml-1 or > 5.42 ng ml-1) was significantly associated with a worse survival (P = 0.02). The predictive value of raised CSF-1 levels was retained whether the first available sample for all patients (n = 82) or the first sample at the start of chemotherapy (n = 41) was considered. Mean CSF-1 levels (n = 14) dropped significantly during six courses of platinum-based chemotherapy (P = 0.02). Although an elevated CA125 concentration appeared to be a prognostic indicator in the total population (n = 82), it was not related to prognosis in the group of patients from whom samples had been drawn at the start of chemotherapy. In a Cox proportional hazards model, CSF-1, but not CA125, was significantly associated with outcome following adjustment for stage, grade and degree of surgical clearance.

[1]  O. Kallioniemi,et al.  Prognostic significance of dna index, multiploidy, and S‐phase fraction in ovarian cancer , 1988, Cancer.

[2]  J. Pollard,et al.  Regulation of colony-stimulating factor 1 during pregnancy , 1986, The Journal of experimental medicine.

[3]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[4]  P. Schwartz,et al.  Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. , 1989, International journal of radiation oncology, biology, physics.

[5]  V. Praloran Structure, biosynthesis and biological roles of monocyte-macrophage colony stimulating factor (CSF-1 or M-CSF). , 1991, Nouvelle revue francaise d'hematologie.

[6]  B. Cocks,et al.  Activation and proliferation signals in murine macrophages. Biochemical signals controlling the regulation of macrophage urokinase-type plasminogen activator activity by colony-stimulating factors and other agents. , 1991, Blood.

[7]  R. Bast,et al.  Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[8]  B. Gullberg,et al.  Prognostic factors in malignant epithelial ovarian tumors. , 1983, Gynecologic oncology.

[9]  E. Stanley,et al.  Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells , 1980, Journal of Cell Biology.

[10]  J. Horiguchi,et al.  CSF-1 and C-FMS gene expression in human carcinoma cell lines. , 1988, Biochemical and biophysical research communications.

[11]  A. Wolkoff,et al.  Macrophages specifically regulate the concentration of their own growth factor in the circulation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Hawkins,et al.  The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. , 1989, British Journal of Cancer.

[13]  E. Stanley Colony-stimulating factor (CSF) radioimmunoassay: detection of a CSF subclass stimulating macrophage production. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[15]  E. Stanley,et al.  The interaction of 125I-colony-stimulating factor-1 with bone marrow-derived macrophages. , 1986, The Journal of biological chemistry.

[16]  C. Redman,et al.  Peritoneal trauma releases CA125? , 1988, British Journal of Cancer.

[17]  R. Bast,et al.  Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. , 1989, The Journal of clinical investigation.

[18]  H. Egami,et al.  Evaluation of Serum CA125 Values in Healthy Individuals and Pregnant Women , 1986, The American journal of the medical sciences.

[19]  F. Beuvon,et al.  Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells? , 1990, Journal of cellular biochemistry.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  E. Stanley,et al.  Purification of the colony-stimulating factor 1 receptor and demonstration of its tyrosine kinase activity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Robert A. Edwards,et al.  High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. , 1988, International journal of radiation oncology, biology, physics.

[23]  R. Arceci,et al.  Apparent role of the macrophage growth factor, CSF-1, in placental development , 1987, Nature.

[24]  V. Praloran,et al.  Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. , 1989, Blood.

[25]  P. Tynan,et al.  Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy , 1982, Cell.

[26]  L. Yee,et al.  Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. , 1990, The American journal of pathology.

[27]  A. Belch,et al.  Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. , 1991, Blood.

[28]  A. Mantovani,et al.  Induction of monocyte migration by recombinant macrophage colony-stimulating factor. , 1988, Journal of immunology.

[29]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[30]  D.,et al.  Regression Models and Life-Tables , 2022 .